According to the research report titled ‘Global Plasma Therapy Market Size study, By Type (Pure PRP, Leucocyte-rich PRP, Pure Platelet-rich Fibrin (PRF), Leukocyte-rich Fibrin (L-PRF)), By Source (Autologous, Allogenic), By Application (Orthopedics, Dermatology, Dental, Cardiac Muscle Injury, Nerve Injury, Others), By End User (Hospitals & Clinics, Research Institutions), and Regional Forecasts 2022-2028, available with MarketStudyReport, global plasma therapy market accounted for USD 261.08 million in 2021 and is projected to reach USD 653.3 million through 2028, recording a CAGR of 14% during the review period.

The increasing frequency of sports injuries, the rising prevalence of orthopedic disorders, and the growing popularity of platelet-rich plasma in therapeutic applications are some of the chief factors driving the growth of global plasma therapy market.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/5065457/  

For those unaware, plasma in blood carries vital hormones, nutrients, and proteins to the body parts. Moreover, the primary objective is to transfer the immunity of a healthy individual to another patient, as well as it includes numerous antibodies that aid in curing various diseases.

Aside from this, the improving economic conditions and increasing expenditure in the healthcare sector will add traction to the overall market growth. However, the lack of reimbursement policies and restricted usage of platelet-rich plasma (PRP) for patients with diabetes and kidney ailments are likely to hamper the growth of the market over the forecast period.

As per type, the market is divided into pure platelet-rich fibrin (PRF), leucocyte-rich PRP, pure PRP, and leukocyte-rich fibrin (L-PRF). Moving on to the source type, the plasma therapy industry is fragmented into allogeneic and autologous segments.

Citing the application spectrum, the market is segmented into nerve injury, cardiac muscle injury, dental, dermatology, orthopedics, and others. With respect to the end-user terrain, the industry is segregated into research institutions and hospitals & clinics segments.

From the regional point of view, North America is anticipated to hold the largest market share during the review period, owing to the increasing investment in R&D activities and the growing presence of leading players in the region.

While Asia-Pacific plasma therapy market is expected to record a modest CAGR over the forecast period, primarily ascribed to the rising geriatric population and increasing prevalence of orthopedic disorders.

Octapharma AG, China Biologic Products Inc., The Bio Products Laboratory, LFB S.A., Kedrion S.p.A., Grifols International S.A., CSL Limited, Biotest AG, Cambryn Biologics LLC, and BioLife Plasma Services are the leading companies influencing global plasma therapy market.